Navigation Links
Prologue Acquisition Update and Termination of Linkcon Business Combination
Date:9/9/2008

any doing business as Linkcon ("Linkcon") regarding the previously announced non-binding letter of intent to combine Encorium and Linkcon (the "Business Combination"). The Board of Directors believes that in the course of negotiations the terms of the proposed Business Combination changed materially to the detriment of the Company and its shareholders since the term sheet with respect to the Business Combination was executed on June 12, 2008. As a result, on September 3, 2008 the Board of Directors decided to end talks with Linkcon and position Encorium to pursue its own growth strategy.

Kai Lindevall, M.D., Ph.D., Encorium's Chief Executive Officer stated, "We are excited to have Prologue join us. As a result of the acquisition of Prologue we believe we will be able to become one of the strongest oncology specialized CROs in the United States and Europe. Our short-to-mid-term strategy is to focus our growth in three main therapeutic areas, namely cardiovascular, vaccines and oncology. Since our globalization strategy remains unchanged, we feel that the services we can provide in the aforementioned areas constitute an excellent platform for further growth on the global arena."

Tom Ludlam, President and CEO of Prologue, stated: "We remain excited about the potential of merging Prologue's significant oncology expertise with Encorium, and feel that this transaction will provide our existing and potential customers with a best-in-class oncology CRO with a geographic footprint that includes over one billion people in North America, Western/Central/Eastern Europe, Scandinavia, and the Baltics."

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopha
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008
2. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
3. Further Acquisition for Schofield Media Group LLC
4. HealthSouth Finalizes Acquisition of Rehabilitation Unit at Medical Center of Arlington
5. China Healthcare Acquisition Corp Signs Definitive Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd.
6. Immucor Closes BioArray Acquisition
7. IPC The Hospitalist Company Completes Acquisition of Hospitalists of America
8. Veridex Completes Acquisition of Immunicon Corporation Assets
9. iCAD Completes Acquisition of CAD Sciences
10. BELLUS Health announces closing of Innodia acquisition
11. Tricom Document Management Expands Onshore Services with Acquisition of Pacific Data Centers, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Linda Cade as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... recognize Linda with this important honor,” said NAPW President ...
(Date:6/1/2015)... 02, 2015 The National Association ... Cornett, DSL, LSSBB (C), First Sergeant A Co., 15BSB ... of the Year Circle. She is recognized with this ... the nation's leading networking organization exclusively for professional women, ... Local Chapters. , “I'm pleased to recognize Sergeant Cornett ...
(Date:6/1/2015)... Ticket Down announces that the Golden State Warriors ... and now will face the Cleveland Cavaliers in the ... Oracle Arena in Oakland and the Quicken Loans Arena in ... season, the Golden State Warriors were the elite team that ... from their playoff failures from the year and riding the ...
(Date:6/1/2015)... CO (PRWEB) June 01, 2015 Atagi ... they have been named an Ultherapy® Ultra ... Plastic Surgery and Skin Aesthetics is one of only ... as a premier treatment provider. , Atagi Plastic ... in the Denver area has led the practice to ...
(Date:6/1/2015)... 2015 Rio Salado College’s Dental Clinic ... young adults this summer. , The clinics take place Friday, ... 3 p.m. at the Rio Salado Dental Clinic. The clinic ... “A big goal for us is to offer services to ... students,” said Nikki Shipp, Clinical Coordinator for Rio’s dental hygiene. ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Kids Receive Complimentary Dental Services at Rio Salado Dental Clinic 2
... Dental Laser Market, SAN CLEMENTE, Calif., Feb. ... Inc. (Nasdaq: BLTI ) announced the,formation of ... laser,division, Lasers4Dentistry, and a laser therapy division,Technology4Therapy. Jeffrey ... and Keith G. Bateman, Biolase,s former Executive Vice ...
... Va., Feb. 21 Federal Health Information,Technology (IT) spending ... $4.5,billion in 2013 at a compound annual growth rate ... IT market, according to a new report by,INPUT, the ... robust, several things remain in the way of even,more ...
... and Water Reuse are Honored, NEW ... curricular solution for pharmacy education, has been,awarded ... Electronic Publication or,Product from the Professional/Scholarly Publishing ... In addition, the McGraw-Hill,reference, Water Reuse: Issues, ...
... release is available in Spanish . , ... Country, Maria Luisa de Francisco Maiz provided a clinical-forensic evaluation ... that influence the length of legal time periods. , Brain ... only for their high incidence but also because they mainly ...
... There are numerous antidepressant medications currently on ... the debilitating symptoms of depression even with treatment. ... 15th issue of Biological Psychiatry set out to ... serotonin and norepinephrine reuptake inhibitors (SNRIs), like venlafaxine ...
... . , Ikerlan-IK4 (CIC microGUNE Microfluidics Unit - ... device that enables the verification of the optimum conditions for ... a microelectrode that measures the impedance and temperature of the ... be monitored from the moment of its extraction, during its ...
Cached Medicine News:Health News:Former Biolase CEO & EVP Launch Technology4Medicine 2Health News:Federal Health IT Market to Reach $4.5 Billion by 2013 2Health News:McGraw-Hill Professional Products Win Awards From Association of American Publishers 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 3Health News:Comparison of venlafaxine and SSRIs in the treatment of depression 2Health News:A device that measures optimum state of an organ prior to transplanting has been patented 2
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
(Date:6/1/2015)... , June 1, 2015 /CNW Telbec/ -  Ergoresearch Ltd ... and known under the « Équilibre, orthèses et ... Ended on March 31, 2015. All dollar amounts in the ... for the third quarter of fiscal year 2015 ended this ... to revenues of $ 3,823,151 for the quarter ended March ...
(Date:6/1/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a ... therapies in new orphan drug indications, announced that it ... live webcast today, June 1, 2015, at 5:30 p.m. ... data from its Phase I/II study of VAL-083 ...
Breaking Medicine Technology:OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 2DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 3DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 4
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that ... Drugs Advisory Committee (ODAC) recommended approval of Afinitor® ... advanced neuroendocrine tumors (NET) of pancreatic origin. ... data from the everolimus RADIANT (RAD001 In Advanced ...
... 12, 2011 MSA (NYSE: MSA ), the ... that protect people,s health and safety, announced today that it ... via the Internet on Thursday, April 28, 2011 at 10:00 ... Investors and interested parties will have the opportunity ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10MSA Schedules First Quarter Earnings Webcast 2
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... is a latex-free unisex system that ... catheterization designed to reduce the risk ... includes a 100% latex-free Mentor Self-Cath ... tab makes it easy to use, ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: